Course offering number:0805-301
Course ID:
1462
Generic Drug Approvals
May 14-16, 2008
New Brunswick, NJ
Robert J. Anderson, Esq.; Vice President, Scientific Affairs, Nycomed
Robert J. Anderson, Esq., is Vice President, Scientific Affairs
at Nycomed, a leading manufacturer of multi-source topical
products. He has over 15 years of experience in regulatory
and legal affairs, patent law, pharmaceutical research and
development, clinical research and quality assurance. Mr.
Anderson received his B.S. from Northwestern University
(Neurobiology & Physiology) and a J.D. from the John Marshall
Law School.
Michael A. Swit, Esq.; Vice President Life Sciences, The Weinberg Group Inc.
Michael A. Swit, Esq., is Vice President, Life Sciences at
The Weinberg Group Inc., a premier scientific and regulatory
consulting firm in the Life Sciences. Since 1984 he has been
both in private practice with McKenna & Cuneo and Heller
Ehrman, and as Vice President, General Counsel and Secretary
of Par Pharmaceutical. He also served from 1994 to 1998 as
CEO of FDANews.com.
Gary L. Yingling, Esq.; Partner, Kirkpatrick & Lockhart Preston Gates Ellis, LLP
Gary L. Yingling, Esq. is a Partner with the law firm of Kirkpatrick
& Lockhart Preston Gates Ellis LLP. Mr. Yingling served in FDA’s
Office of General Counsel as a trial attorney, as Associate Chief
Counsel for Veterinary Medicine, Deputy Chief Counsel for
Administration and as Director of FDA’s Over-the-Counter Drug
Review. He is counsel to the International Society for Regulatory
Toxicology and Pharmacology, is Editor of the Guide to Good
Clinical Practices, and serves on the Editorial Board of both the
Clinical Research Practices and Drug Regulatory Affairs and
Regulatory Toxicology and Pharmacology journals.
|